Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

  • Long Idea of the Year

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

  • Quickster: Update on Corbus

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. To see all of his column and his latest comments, go to his Stock Gumshoe page.] [Author’s note: This commentary has been […]

  • The 12 Biotechs of Christmas: Six

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

  • The 12 Biotechs of Christmas: Five

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

  • The 12 Biotechs of Christmas: Four

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

  • The Twelve Biotechs of Christmas: Two

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

  • Such A Pleasant Stay

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

  • Sea of Tranquility

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]

  • Tropic of Palatin

    [Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his thoughts and opinions are his own. His previous columns and recent comments can be found on his Stock Gumshoe page.] “He had never seen her body so abandoned, so unconscious […]

  • Ten Common Biotech Investing Mistakes

    [Ed. Note: Dr. KSS writes about medicine biotech stocks for the Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page for his past articles and most recent comments.] Assessing biotechnology stocks involves use of lots of mental microscopes and magnifying lenses. But the task […]

  • Quickster: T2 Biosystems ($TTOO)

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page to see his biography, latest comments and past articles.] About 18 months ago, I came across tiny Boston-area diagnostics start-up […]

  • The State of Things: Ruction at Regulus

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]

  • Conflict Diamonds

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]

  • Recent Author Comments

    On Long Idea of the Year
    I'm on the west coast this am for personal travel...will check back into this one when I get home. Thanks for bringing it up. Glenn and I picked it apart and it looked good in 2014, but it got trampled in a rush of better picks. Just remember, the immuno-o[...]
    On Long Idea of the Year
    Scorpio: he died of hepatocellular carcinoma, which is why he underwent orthotopic liver transplantation. A sort of Lou Reed scenario. He likely had micrometastases at OLT that simply flourished when his immune system was chronically throttled back with ta[...]
    On Long Idea of the Year
    Hi Sharon, yes they finally did. I think the issue is understaffing: there is literally one guy for "outreach" projects that cultivate new business in new sources, and my time with him was short because he was headed to the middle east. Apparently a number[...]
    On Long Idea of the Year
    A business associate and I have approached T2 because we may have a pathway for them to place their devices in Chinese hospitals, the world's biggest healthcare market. We've conducted a survey of Chinese medical attitudes, and most view the present system[...]
    On Long Idea of the Year
    Frank: a lecherous older guy spies a beautiful young woman in a park, and by stealth, he follows her home. When she gets there, he sees she's married, and she greets her husband at the door. Not to be stymied, he finds an old bottle in the trash can, and h[...]
    On Long Idea of the Year
    http://www.gbcnv.edu/hickson/waterholeike.html John, remember this, um, character?[...]
    On Long Idea of the Year
    Frank: I feel you are correct. I've known more than a few sociopathic people for whom a recurring thrill in life is doing something illicit and getting away with that facing no consequences. This pertains strongly to the sexual realm. I know (and not in th[...]
    On Long Idea of the Year
    Tough to say. It could have a mild suppressive effect on biotech as a sector. Personally I regard our long ideas as having made things fertile for our reader investors in a relatively market-condition-proof way, but we have to remember that the Biotech Pox[...]
    On Long Idea of the Year
    Do you project often, bigongit? Forgot your Abilify?[...]
    On Long Idea of the Year
    Curt: you raise a cluster of interesting and relevant issues. It does need to be pointed out that one can be on ART and have no detectable plasma HIV RNA but still have infected semen, and this fact is something that clinicians make considerable efforts to[...]
    On Long Idea of the Year
    $TRIL remains a beloved stock. here. At one time it was getting heavy coverage in the threads. I have a long position and am mystified as to what I regard as its underperformance; since I can't right now sense that a break in the weather is coming, I've c[...]
    On Long Idea of the Year
    Thanks Mosley. I really appreciate it. I am indeed juggling subcontractors, all really carefully selected after doing interviews and getting references. The ones I've gotten are doing so loving a job I practically want them to sign their work. But things a[...]
    On Long Idea of the Year
    I have a large block of $APTO too, and hadn't entered that on the table. Big holding for me.[...]
    On Long Idea of the Year
    Hi John: In general, the m.o. for a phase 3 trial is that patients prospectively are reviewed in practices of all the widely-dispersed principal investigators in far flung sites. A patient that is willing to proceed, and that appears to pass muster as a go[...]
    On Long Idea of the Year
    Good questions all. As regards when the ice floes will break up at APTO and we get movement, I think really any time in 3Q or 4Q, and possibly at year end. Remember that if and when the APTO 253 crystallization issue is solved, that drug resumes phase 2b t[...]
    On Long Idea of the Year
    Oh definitely not. I plan on doing this for the next 20 years at least.[...]
    On Long Idea of the Year
    My long-treatment column of $APTO won't be done til I finish moving, which is dragging out for complex reasons. An introductory summary about Aptose is presented with the "12 Biotechs of Christmas" material. Paul's comments above are very correct. It's gen[...]
    On Long Idea of the Year
    You're not missing anything. It's labile, it channels, it chatters. Just park and ignore. I really believe this one will do fine and pay off handsomely. Patience. I'd not fret over the quotidian here. Still not on everyone's radar, but it will be.[...]
    On Long Idea of the Year
    Hi Peter: Glenn Newberry and I are trying to corral Mike Martin and Neil Solomons for some follow-up interviewing next week. We've tried to check in every 4-6 months with them. I'll certainly pump them for enrollment status....an announcement of 25 per cen[...]
    On Long Idea of the Year
    Hi moriarty: I confess I did not know that about Lonza, but they are class act and truth be told probably the best in the business. I have seriously considered investing in them before because they are so highly regarded. Voclosporin is indeed difficult to[...]

    This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.